BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Reports Third Quarter 2025 Financial Results

Artivion (AORT)ArtivionEarnings

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million , or $0.13 per fully diluted share, and non-GAAP

Related news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

FEMYFEMASYS2026-08-14 20:05 EST

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

PAVMPAVmed2026-08-14 12:00 EST

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PAVMPAVmed2026-08-13 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

ICUSeaStar Medical2026-08-12 20:05 EST

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

STXSStereotaxis2026-08-11 20:01 EST

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

NEPHNephros2026-08-06 20:10 EST

Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026

APYXApyx Medical2026-08-06 20:05 EST

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
28.08 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States